Trials / Completed
CompletedNCT00390520
Efficacy and Safety of Vildagliptin Versus Placebo in Patients With Type 2 Diabetes
A Single-center, Double-blind, Randomized, Placebo-controlled, Cross-over Study to Assess the Effect of Vildagliptin on Glucagon Counterregulatory Response During Hypoglycemia in Patients With Type 2 Diabetes.
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 28 (estimated)
- Sponsor
- Novartis · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- —
Summary
This mechanistic study is designed to investigate the effect of vildagliptin on the sensitivity of the a-cell to glucose under hypoglycemic conditions in patients with type 2 diabetes (T2DM).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Vildagliptin |
Timeline
- Start date
- 2006-09-01
- Primary completion
- 2007-09-01
- Completion
- 2007-09-01
- First posted
- 2006-10-20
- Last updated
- 2020-02-11
Locations
1 site across 1 country: Switzerland
Source: ClinicalTrials.gov record NCT00390520. Inclusion in this directory is not an endorsement.